|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward
Datamonitor, Sep 2007, Pages: 503
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential.
Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
Scope
Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for 17 tumor types
Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2016 with product-specific assumptions
Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication
Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Highlights
The current solid tumor pipeline contains at least 707 unique agents, 9% of which are in late-phase development. These products cover a vast array of anticancer drug classes, including antihormonal therapies, cytotoxics, gene therapies, immunotherapies, photodynamic therapies, radiotherapeutics, targeted therapies and therapeutic vaccines. The late-phase pipeline contains equal amounts of cytotoxics and targeted therapies. The Phase I and II pipelines contain more than twice as many targeted therapies as cytotoxics. As such, it is clear that increasing diversity in terms of drug targets may result in greater treatment options in years to come if positive clinical data is generated. Despite high levels of unmet need and relatively healthy pipelines for most indications, no major breakthroughs are expected by current late-phase products aside from incremental increases in efficacy and reduced toxicity. This indicates a heavy reliance on the earlier-phase pipeline for further breakthroughs in terms of treatment of solid tumors.
Reasons to Purchase
Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2016
Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction
Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
Customers who bought this item also bought
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Pipeline and Commercial Insight: Hepatitis C - High Unmet Need Drives Rapid Innovation
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
Treatment Algorithms: Colorectal Cancer 5th Edition - New Gold Standards Emerge But Unmet Need Remains
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
|
|
|
|
